Generic Product News (May 2016)

Pharmacy Times, May 2016 Skin & Eye Health, Volume 82, Issue 5

Read about the new generic products featured in May.

Camber Pharmaceuticals, Inc

Compare to: Valcyte (Hoffman La Roche)

Indication: Camber Pharmaceuticals recently launched valganciclovir, the therapeutic equivalent of Hoffman La Roche’s Valcyte tablets, in a 450-mg dosage strength. The product is indicated to treat cytomegalovirus infection of the eye in patients with AIDS. Valganciclovir is available in a 60-count bottle.

Dosage Form: Tablets: 450 mg

For More Information: camberpharma.com

Raloxifene Hydrochloride Tablets USP, 60 mg Marketed by: Glenmark Pharmaceuticals, Inc

Compare to: Evista (Eli Lilly and Company)

Indication: Glenmark Pharmaceuticals, Inc, has been granted FDA approval for Raloxifene Hydrochloride Tablets, the generic equivalent of Eli Lilly’s Evista, in a 60-mg dosage strength. The product is a selective estrogen receptor modulator indicated to treat osteoporosis and reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

Dosage Form: Tablets: 60 mg

For More Information: glenmarkpharma.com

Diclofenac Sodium Topical Gel 1%Marketed by: Amneal Pharmaceuticals, LLC

Compare to: Voltaren Gel 1% (Novartis Pharmaceuticals Corporation)

Indication: Amneal Pharmaceuticals, LLC, recently launched Diclofenac Sodium Topical Gel 1%, the therapeutic equivalent of Novartis Pharmaceuticals’ Voltaren Gel 1%. The product is a nonsteroidal anti-inflammatory drug indicated to treat pain associated with osteoarthritis in joints amenable to topical treatment, such as the knees and the hands.

Dosage Form: 1% gel

For More Information: amneal.com

Rivastigmine Tartrate Capsules, USP, 1.5 mg, 3 mg, 4.5 mg, 6 mg Marketed by: Aurobindo Pharma USA, Ltd

Compare to: Exelon Capsules (Novartis Pharmaceuticals Corporation)

Indication: Aurobindo Pharma, Ltd, recently received FDA approval for Rivastigmine Tartrate Capsules, USP, the therapeutic equivalent of Novartis Pharmaceuticals’ Exelon, in 1.5-, 3-, 4.5-, and 6-mg dosage strengths. The product is indicated to treat mild to moderate dementia associated with Parkinson’s disease.

Dosage Form: Capsules: 1.5, 3, 4.5, and 6 mg

For More Information: aurobindousa.com